Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Besremi Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.04.50

    Besremi (ropeginterferon alfa-2b-njft) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.04.50 alerts

    Get alerted when Policy 05.04.50 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Besremi (ropeginterferon alfa-2b-njft) for adults with polycythemia vera and specified compendial hematologic and lymphoid malignancies. It establishes initial and continuation approval criteria, authorization duration, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyBesremi (ropeginterferon alfa-2b-njft) Coverage and Prior Authorization
    Policy CodePolicy 05.04.50
    Change TypeNo material change
    Effective DateSep 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionPrior authorization is required for Besremi.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1FDA-approved indication
    6Compendial use categories
    12 monthsStandard authorization duration
    2 per 28 daysQuantity limit per presentation

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    Besremi formulations
    28 daysQuantity-limit period

    Coverage Criteria

    Initial Therapy: Essential Thrombocythemia

    Authorization for 12 months may be granted for initial treatment of essential thrombocythemia when ANY of the following is met:

    ANY of the following

    • The member has had an inadequate response or loss of response to prior cytoreductive therapy, such as anagrelide, hydroxyurea, or peginterferon alfa-2a (Pegasys).
    • Peginterferon alfa-2a (Pegasys) is unavailable.

    Initial Therapy: Myelofibrosis

    Authorization for 12 months may be granted for treatment of myelofibrosis when the following criterion is met:

    Peginterferon alfa-2a (Pegasys) is unavailable.

    Initial Therapy: Polycythemia Vera

    Authorization for 12 months may be granted when the following criterion is met:

    The member is being treated for polycythemia vera.

    Initial Therapy: Chronic Myeloid Leukemia

    Authorization for 12 months may be granted when the following criterion is met:

    The member is pregnant and is receiving initial treatment for chronic myeloid leukemia.

    Initial Therapy: Systemic Mastocytosis

    Authorization for 12 months may be granted for treatment of systemic mastocytosis when the following criterion is met:

    Peginterferon alfa-2a (Pegasys) is unavailable.

    Initial Therapy: Mycosis Fungoides/Sézary Syndrome

    Authorization for 12 months may be granted for treatment of mycosis fungoides/Sézary syndrome when the following criterion is met:

    Peginterferon alfa-2a (Pegasys) is unavailable.

    Initial Therapy: Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders

    Authorization for 12 months may be granted for treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders when the following criterion is met:

    Peginterferon alfa-2a (Pegasys) is unavailable.

    Initial Therapy: Adult T-Cell Leukemia/Lymphoma

    Authorization for 12 months may be granted for treatment of adult T-cell leukemia/lymphoma when the following criterion is met:

    Peginterferon alfa-2a (Pegasys) is unavailable.

    Continuation Therapy: Myeloproliferative Neoplasms

    Authorization for 12 months may be granted for continuation therapy when the following criterion is met:

    The member is experiencing benefit from therapy, as evidenced by improvement in symptoms and/or disease markers, such as morphological response, reduction or stabilization in spleen size, or improvement of thrombocytosis or leukocytosis.

    Continuation Therapy: All Other Covered Indications

    Authorization for 12 months may be granted for continued treatment of all other indications listed in the coverage criteria when the following criteria are met:

    ALL of the following

    • The member is requesting reauthorization for an indication in the coverage criteria that is not otherwise addressed under continuation therapy for myeloproliferative neoplasms.
    • There is no evidence of unacceptable toxicity while the member is receiving the current regimen.
    • There is no evidence of disease progression while the member is receiving the current regimen.

    Besremi (ropeginterferon alfa-2b-njft) is considered not medically necessary for members who do not meet the criteria set forth above.

    Members currently receiving Besremi as samples or through the manufacturer's patient assistance program are required to meet the criteria for initial approval. This ensures that members are treated equally regardless of their provider's ability to access medication samples.

    Authorization and Provider Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required for Besremi. Initial authorization may be granted for 12 months when the applicable indication-specific criteria are met.

    • Essential thrombocythemia: Either inadequate response or loss of response to prior cytoreductive therapy, or Pegasys (peginterferon alfa-2a) is unavailable.
    • Myelofibrosis: Pegasys is unavailable.
    • Polycythemia vera: The member is being treated for polycythemia vera.
    • Chronic myeloid leukemia: Initial treatment is for chronic myeloid leukemia in pregnancy.
    • Systemic mastocytosis, mycosis fungoides/Sézary syndrome, primary cutaneous CD30+ T-cell lymphoproliferative disorders, or adult T-cell leukemia/lymphoma: Pegasys is unavailable.
    Prior Authorization

    Continuation Authorization

    Reauthorization may be granted for 12 months when the member continues to meet the applicable continuation criteria and remains appropriate for Besremi therapy.

    Clinical Background

    Besremi (ropeginterferon alfa-2b-njft) is an interferon-based therapy used for adults with polycythemia vera and specified hematologic and lymphoid disorders. Covered uses include polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myeloid leukemia, systemic mastocytosis, mycosis fungoides or Sézary syndrome, primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and adult T-cell leukemia/lymphoma.

    Initial Therapy

    Essential thrombocythemia: Initial authorization

    Authorization of 12 months may be granted when at least one of the following criteria is met:

    ONE of

    • The member has had an inadequate response or loss of response to prior cytoreductive therapy, such as anagrelide, hydroxyurea, or peginterferon alfa-2a (Pegasys).
    • Peginterferon alfa-2a (Pegasys) is unavailable.

    Myelofibrosis: Initial authorization

    Authorization of 12 months may be granted when both of the following are met:

    ALL of the following

    • The member has myelofibrosis.

    Continuation Therapy

    Myeloproliferative neoplasms: Continuation authorization

    Authorization of 12 months may be granted when:

    The member is experiencing benefit from therapy, as evidenced by improvement in symptoms and/or disease markers.

    Examples include morphological response, reduction or stabilization in spleen size, or improvement of thrombocytosis or leukocytosis.

    All other indications: Continuation authorization

    Authorization of 12 months may be granted for continued treatment when both of the following are met:

    ALL of the following

    • The member is requesting continued treatment for a covered indication listed in the coverage criteria section.
    • There is no evidence of unacceptable toxicity or disease progression while the member is on the current regimen.

    Required Prior Therapy

    StepPrior therapy requirementRequired outcome
    1Prior cytoreductive therapy such as anagrelide, hydroxyurea, or peginterferon alfa-2a (Pegasys) for essential thrombocythemiaInadequate response or loss of response to prior therapy
    StepIndicationsPegasys requirement
    1Myelofibrosis; systemic mastocytosis; mycosis fungoides/Sézary syndrome; primary cutaneous CD30-positive T-cell lymphoproliferative disorders; or adult T-cell leukemia/lymphomaPeginterferon alfa-2a (Pegasys) is unavailable before Besremi is initiated

    Besremi Quantity Limits

    Quantity Limit
    Quantity limit2 prefilled syringes per 28 days
    Quantity Limit
    Quantity limit2 pens per 28 days
    Quantity Limit
    Allowed quantity2 prefilled syringes per 28 days
    Quantity Limit
    Allowed quantity2 pens per 28 days
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyBesremi (ropeginterferon alfa-2b-njft) Coverage and Prior Authorization
    Policy CodePolicy 05.04.50
    Change TypeNo material change
    Effective DateSep 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateNot specified
    Key ActionPrior authorization is required for Besremi.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Provider RequirementsClinical BackgroundInitial TherapyContinuation TherapyRequired Prior TherapyBesremi Quantity Limits
    • Myeloproliferative neoplasms: The member is experiencing benefit from therapy, evidenced by improvement in symptoms and/or disease markers, such as a morphological response, reduction or stabilization in spleen size, or improvement of thrombocytosis/leukocytosis.
    • All other covered indications: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.

    Unsupported block type: documentation

    Documentation Required

    Prior Cytoreductive Therapy

    For initial treatment of essential thrombocythemia, document an inadequate response or loss of response to prior cytoreductive therapy when relying on this pathway for authorization.

    • Examples of prior cytoreductive therapy include anagrelide, hydroxyurea, or Pegasys (peginterferon alfa-2a).
    Denial Risk

    Criteria Not Met

    Besremi is not medically necessary when the member does not meet the applicable initial- or continuation-approval criteria. Members receiving Besremi as samples or through the manufacturer's patient assistance program must still meet the initial-approval criteria.

    • Coverage is subject to the same criteria regardless of whether medication was obtained through samples or a manufacturer patient assistance program.
    Denial Risk

    Lack of Treatment Benefit or Safety

    Continuation coverage may be denied when Besremi is not providing treatment benefit or when safety or disease-status concerns make ongoing therapy inappropriate.

    • For myeloproliferative neoplasms, lack of improvement in symptoms or disease markers may indicate insufficient benefit.
    • Unacceptable toxicity or disease progression while on the current regimen does not meet the continuation criteria.
  1. Peginterferon alfa-2a (Pegasys) is unavailable.
  2. Polycythemia vera: Initial authorization

    Authorization of 12 months may be granted for treatment when:

    The member has polycythemia vera.

    Chronic myeloid leukemia: Initial authorization

    Authorization of 12 months may be granted for initial treatment when both of the following are met:

    ALL of the following

    • The member has chronic myeloid leukemia.
    • The member is pregnant.Pregnancy

    Other covered indications: Initial authorization

    Authorization of 12 months may be granted when both an applicable indication and Pegasys unavailability are established:

    ALL of the following

    • ONE of the following indications

      • The member has systemic mastocytosis.
      • The member has mycosis fungoides or Sézary syndrome.
      • The member has a primary cutaneous CD30-positive T-cell lymphoproliferative disorder.
      • The member has adult T-cell leukemia/lymphoma.
    • Peginterferon alfa-2a (Pegasys) is unavailable.